Dissociation between adipose nitric oxide synthase expression and tissue metabolism.
BACKGROUND
Nitric oxide synthase (NOS) expression in adipose tissue is increased in obese subjects. The functional relevance is not known.


OBJECTIVE
The objective was to compare adipose tissue metabolism between obese men with greater or lower adipose endothelial NOS (eNOS) or inducible NOS (iNOS) expression.


METHODS
The design was an open-labeled prospective study.


METHODS
The study took place at an academic clinical research center.


METHODS
The patients included 14 obese (32 +/- 0.6 kg/m2) and eight normal-weight (23 +/- 2 kg/m2) healthy men.


METHODS
Microdialysis catheters in abdominal sc adipose tissue and in vastus lateralis were perfused with N-omega-nitro-L-arginine methyl ester (L-NAME) or N-omega-nitro-D-arginine methyl ester (D-NAME). Then, incremental isoproterenol concentrations were added to the perfusate.


METHODS
Microdialysate glycerol was the main outcome measure.


RESULTS
Tissue perfusion and microdialysate glycerol concentrations at baseline and during isoproterenol stimulation were similar in obese men with high or low eNOS or iNOS expression during both L-NAME and D-NAME. During D-NAME, basal and maximal isoproterenol stimulated glycerol were similar in lean and in obese men. However, in lean men, the dose-response relationship between isoproterenol and glycerol was shifted towards the left (P < 0.0001). NOS inhibition with L-NAME had no effect on basal or isoproterenol-stimulated glycerol in the obese group in skeletal muscle or in adipose tissue. In contrast, L-NAME augmented the lipolytic response in lean subjects in both tissues.


CONCLUSIONS
Differences in eNOS and iNOS mRNA expression at the adipose tissue level may have a limited effect on lipolysis and tissue perfusion. The lower resting lipolysis in adipose tissue of obese compared with nonobese subjects cannot be explained by a tonic nitric oxide effect.
Engeli
Stefan
S
Franz-Volhard Clinical Research Center, Charité Campus Buch, Wiltbergstrasse 50, 13125 Berlin, Germany.
Boschmann
Michael
M
Adams
Frauke
F
Franke
Gabriele
G
Gorzelniak
Kerstin
K
Janke
Jürgen
J
Luft
Friedrich C
FC
Jordan
Jens
J
D000273:Adipose Tissue / Q000187:drug effects / Q000201:enzymology*; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000328:Adult; D001835:Body Weight; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D015971:Gene Expression Regulation, Enzymologic; D005990:Glycerol / Q000378:metabolism; D006801:Humans; D007545:Isoproterenol / Q000008:administration & dosage; D008066:Lipolysis / Q000502:physiology; D008297:Male; D017551:Microdialysis; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D052247:Nitric Oxide Synthase Type II / Q000235:genetics* / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics* / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism*; D011446:Prospective Studies
D000318:Adrenergic beta-Agonists; D004791:Enzyme Inhibitors; C496314:NOS3 protein, human; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D007545:Isoproterenol; D005990:Glycerol; D019331:NG-Nitroarginine Methyl Ester